210 related articles for article (PubMed ID: 7572686)
1. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
Probstfield JL; Margitic SE; Byington RP; Espeland MA; Furberg CD
Am J Cardiol; 1995 Sep; 76(9):47C-53C. PubMed ID: 7572686
[TBL] [Abstract][Full Text] [Related]
2. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg CD; Adams HP; Applegate WB; Byington RP; Espeland MA; Hartwell T; Hunninghake DB; Lefkowitz DS; Probstfield J; Riley WA
Circulation; 1994 Oct; 90(4):1679-87. PubMed ID: 7734010
[TBL] [Abstract][Full Text] [Related]
3. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Byington RP; Evans GW; Espeland MA; Applegate WB; Hunninghake DB; Probstfield J; Furberg CD
Circulation; 1999 Jul; 100(3):e14-7. PubMed ID: 10411862
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
Byington RP; Furberg CD; Crouse JR; Espeland MA; Bond MG
Am J Cardiol; 1995 Sep; 76(9):54C-59C. PubMed ID: 7572688
[TBL] [Abstract][Full Text] [Related]
5. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study.
Espeland MA; Applegate W; Furberg CD; Lefkowitz D; Rice L; Hunninghake D
Am J Epidemiol; 1995 Nov; 142(10):1011-9. PubMed ID: 7485045
[TBL] [Abstract][Full Text] [Related]
6. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial.
Hodis HN; Mack WJ; LaBree L; Selzer RH; Liu C; Liu C; Alaupovic P; Kwong-Fu H; Azen SP
Ann Intern Med; 1996 Mar; 124(6):548-56. PubMed ID: 8597317
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group.
Control Clin Trials; 1992 Aug; 13(4):293-314. PubMed ID: 1330434
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.
Crouse JR; Byington RP; Bond MG; Espeland MA; Sprinkle JW; McGovern M; Furberg CD
Control Clin Trials; 1992 Dec; 13(6):495-506. PubMed ID: 1334821
[TBL] [Abstract][Full Text] [Related]
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
10. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
MacMahon S; Sharpe N; Gamble G; Hart H; Scott J; Simes J; White H
Circulation; 1998 May; 97(18):1784-90. PubMed ID: 9603532
[TBL] [Abstract][Full Text] [Related]
11. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study.
Baldassarre D; Veglia F; Gobbi C; Gallus G; Ventura A; Crepaldi G; Fisicaro M; Rimondi S; Ricci G; Mancini M; Bong MG; Collatina S; Sirtori CR
Atherosclerosis; 2000 Aug; 151(2):575-83. PubMed ID: 10924737
[TBL] [Abstract][Full Text] [Related]
12. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Frisinghelli A; Mafrici A
Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
[TBL] [Abstract][Full Text] [Related]
13. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
Salonen R; Nyyssönen K; Porkkala E; Rummukainen J; Belder R; Park JS; Salonen JT
Circulation; 1995 Oct; 92(7):1758-64. PubMed ID: 7671358
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
15. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
Post Coronary Artery Bypass Graft Trial Investigators
N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
[TBL] [Abstract][Full Text] [Related]
16. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression.
Salonen R; Nyssönen K; Porkkala-Sarataho E; Salonen JT
Am J Cardiol; 1995 Sep; 76(9):34C-39C. PubMed ID: 7572684
[TBL] [Abstract][Full Text] [Related]
17. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
Kroon AA; van Asten WN; Stalenhoef AF
Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
[TBL] [Abstract][Full Text] [Related]
18. Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Kent SM; Coyle LC; Flaherty PJ; Markwood TT; Taylor AJ
Clin Cardiol; 2004 Jan; 27(1):17-21. PubMed ID: 14743850
[TBL] [Abstract][Full Text] [Related]
19. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
[TBL] [Abstract][Full Text] [Related]
20. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
